Castini Diego Carlo, Persampieri Simone, Sabatelli Ludovico, Valli Federica, Ferrante Giulia, Zambelli Daniel, Toriello Filippo, Provenzale Giovanni, Gentile Domitilla, Bursi Francesca, Centola Marco, Carugo Stefano
Division of Cardiology, Heart and Lung Department, San Paolo Hospital, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, IRCCS Cà Granda Ospedale Maggiore Policlinico Foundation, Internal Medicine Department, Cardiology Unit, Milan, Italy.
Cardiology. 2021;146(5):538-546. doi: 10.1159/000515986. Epub 2021 May 7.
This study analyzes the usefulness of the CHA2DS2-VASc score for mortality prediction in patients with acute coronary syndromes (ACSs) and evaluates if the addition of renal functional status could improve its predictive accuracy.
CHA2DS2-VASc score was calculated by using both the original scoring system and adding renal functional status using 3 alternative renal dysfunction definitions (CHA2DS2-VASc-R1: eGFR <60 mL/min/1.73 mq = 1 point; CHA2DS2-VASc-R2: eGFR <60 mL/min/1.73 mq = 2 points; and CHA2DS2-VASc-R3: eGFR <60 mL/min/1.73 mq = 1 point, <30 mL/min/1.73 mq = 2 points). Inhospital mortality (IHM) and post-discharge mortality (PDM) were recorded, and discrimination of the various risk models was evaluated. Finally, the net reclassification index (NRI) was calculated to compare the mortality risk classification of the modified risk models with that of the original score.
Nine hundred and eight ACS patients (median age 68 years, 30% female, 51% ST-elevation) composed the study population. Of the 871 patients discharged, 865 (99%) completed a 12-month follow-up. The IHM rate was 4.1%. The CHA2DS2-VASc score demonstrated a good discriminative performance for IHM (C-statistic 0.75). Although all the eGFR-modified risk models showed higher C-statistics than the original model, a statistically significant difference was observed only for CHA2DS2-VASc-R3. The PDM rate was 4.5%. The CHA2DS2-VASc C-statistic for PDM was 0.75, and all the modified risk models showed significantly higher C-statistics values than the original model. The NRI analysis showed similar results.
CHA2DS2-VASc score demonstrated a good predictive accuracy for IHM and PDM in ACS patients. The addition of renal dysfunction to the original score has the potential to improve identification of patients at the risk of death.
本研究分析了CHA2DS2-VASc评分对急性冠脉综合征(ACS)患者死亡率预测的有效性,并评估加入肾功能状态是否能提高其预测准确性。
使用原始评分系统计算CHA2DS2-VASc评分,并通过3种不同的肾功能不全定义加入肾功能状态(CHA2DS2-VASc-R1:估算肾小球滤过率[eGFR]<60ml/min/1.73m²计1分;CHA2DS2-VASc-R2:eGFR<60ml/min/1.73m²计2分;CHA2DS2-VASc-R3:eGFR<60ml/min/1.73m²计1分,<30ml/min/1.73m²计2分)。记录住院死亡率(IHM)和出院后死亡率(PDM),评估各种风险模型的辨别能力。最后,计算净重新分类指数(NRI),以比较改良风险模型与原始评分的死亡风险分类。
908例ACS患者(中位年龄68岁,30%为女性,51%为ST段抬高型)构成研究人群。在871例出院患者中,865例(99%)完成了12个月的随访。IHM率为4.1%。CHA2DS2-VASc评分对IHM显示出良好的辨别性能(C统计量为0.75)。尽管所有eGFR改良风险模型的C统计量均高于原始模型,但仅CHA2DS2-VASc-R3有统计学显著差异。PDM率为4.5%。CHA2DS2-VASc对PDM的C统计量为0.75,所有改良风险模型的C统计量值均显著高于原始模型。NRI分析显示了类似结果。
CHA2DS2-VASc评分对ACS患者的IHM和PDM显示出良好的预测准确性。在原始评分中加入肾功能不全有可能改善对死亡风险患者的识别。